Author: Nichols Martin|| Date Published: June 10, 2021
Army Contracting Command has awarded Merck (NYSE: MRK) a one-year, $1.2 billion contract to deliver nearly 1.7 million courses of molnupiravir, an investigational oral antiviral agent intended to support the treatment of COVID-19 patients.
The Department of Defense said Wednesday the full contract amount was obligated on the firm-fixed-price contract using Coronavirus Aid, Relief and Economic Security Act funds.
Molnupiravir, also known as MK-4482, is undergoing a late-stage clinical trial, dubbed MOVe-OUT. Merck secured the contract through an online solicitation and will deliver the antiviral drug to the U.S. government once the Food and Drug Administration grants emergency use authorization.
Ridgeback Biotherapeutics works with Merck in the COVID-19 treatment development effort and the latter company expects more than 10 million courses of antiviral therapy to be available at the end of the year.
Kris Levin-Snow, area vice president within AT&T‘s national security group, will now oversee the company’s defense industrial base portfolio in addition…
Rocket Lab has signed a definitive agreement to acquire California-based Motiv Space Systems, adding space robotics and precision spacecraft mechanism…
Sonny Bhagowalia, assistant commissioner for information and technology and chief information officer at U.S. Customs and Border Protection, has received…
NextPoint Group expands intelligence-focused capabilities with UScontracting acquisition by adding expertise in cybersecurity, signals intelligence and data analysis for national…
